Aethlon Medical's Hemopurifier® Gets the Green Light for Cancer Trials
Aethlon Medical, Inc. (NASDAQ: AEMD), a company focused on developing solutions for difficult medical conditions, has received full ethics approval from the Medanta Institutional Ethics Committee. This approval allows them to proceed with a vital safety, feasibility, and dose-finding study of their innovative Hemopurifier® device, aimed at helping cancer patients who have solid tumors unresponsive to standard anti-PD-1 therapies.
Key Details About the Clinical Trial
The Medanta Institutional Ethics Committee approved this clinical trial on September 9, 2024. It will include patients either with stable or progressive disease undergoing monotherapy using anti-PD-1 antibodies, including Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®). Officially referred to as the AEMD-2022-06 Hemopurifier Study, this trial is set to last one year, with annual evaluations following the main study period.
Leadership of Medical Experts
The trial will be spearheaded by Dr. Ashok K. Vaid and his team from the Department of Medical Oncology and Hematology at Medanta. The actual Hemopurifier treatments will be administered by Dr. Puneet Sodhi from the Department of Nephrology, who has become a leading figure in Hemopurifier treatments, performing more procedures than anyone else globally.
Significance of the Approval
Dr. Steven LaRosa, CEO, expressed his satisfaction with the prompt approval from the MIEC, especially given the recent authorizations from various ethical committees in Australia. This multi-center strategy highlights the goal to assess the Hemopurifier’s potential across different cancer types, particularly where tumor-associated exosomes play a role in immune suppression and the progression of disease.
How the Hemopurifier Works
Current clinical data suggests that about 30% of patients receiving Keytruda® and Opdivo® for solid tumors achieve sustained responses. It's thought that tumor-derived extracellular vesicles (EVs) could hinder the effectiveness of these therapies. The Hemopurifier is specifically designed to remove these troublesome vesicles from the bloodstream, potentially improving the effectiveness of the treatments. Early studies have indicated that using the Hemopurifier could significantly reduce EV counts in cancerous plasma samples.
Goals and Expectations for the Trial
Aethlon plans to conduct a trial with 9 to 18 participants to evaluate the safety of their device while observing any adverse effects or significant laboratory changes in the patients receiving treatment. After an initial two-month period on Keytruda® or Opdivo® monotherapy, patients who show no clinical progress will move into the Hemopurifier treatment phase, which will involve one to three treatments within a week. The trial will closely monitor how effectively these treatments can reduce EV concentrations, potentially boosting the body’s natural ability to fight off tumor cells.
Looking Ahead for Aethlon Medical
Aethlon's main goal is to utilize the findings from this trial to design future research studies that focus on the efficacy of the Hemopurifier. This is essential for securing premarket approval from regulatory bodies. Their approach not only aims to enhance cancer treatment strategies but also addresses the significant issue of resistant cancer types, where traditional treatments often fail.
About Aethlon Medical and the Hemopurifier®
Aethlon Medical specializes in creating advanced therapeutic devices that are crucial for tackling complex health issues, including cancer and serious viral infections. The Hemopurifier® stands out as a key innovation, intended to filter harmful exosomes and has shown encouraging results in past studies for its effectiveness in removing dangerous viruses and exosomes from bodily fluids.
The Hemopurifier® has earned recognition from the U.S. Food and Drug Administration (FDA) as a Breakthrough Device. It is positioned to aid patients with severe or metastatic cancer who don't respond to or cannot tolerate existing therapies. It also holds an Investigational Device Exemption (IDE) to treat life-threatening viral infections.
Frequently Asked Questions
What is the primary goal of Aethlon's current trial?
The main objective is to assess the safety and feasibility of the Hemopurifier in patients with solid tumors unresponsive to anti-PD-1 therapy.
How many patients will be involved in the study?
The trial will include approximately 9 to 18 participants based on safety and treatment feasibility.
What experience does the medical team bring to the trial?
Dr. Ashok K. Vaid and Dr. Puneet Sodhi are both highly experienced in oncology and nephrology, respectively, with Dr. Sodhi being a leading expert in Hemopurifier treatments.
How does the Hemopurifier work?
The Hemopurifier is designed to isolate and eliminate harmful extracellular vesicles from the patient's bloodstream, which may enhance the effectiveness of cancer therapies.
What is Aethlon's vision for the Hemopurifier in oncology?
Aethlon aims to validate the Hemopurifier’s utility in clinical settings to optimize treatment outcomes for hard-to-treat cancers and seek further regulatory approval.
